[1]. Robot-assisted radical nephrectomy and inferior vena cava tumor thrombectomy using the novel surgical robot platform, hinotori: Initial experience with two cases.
IJU case reports [巻]7 [号]2 [頁]96 -99 （2024年） [査読] 有
[DOI] [2]. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
Anticancer research [巻]44 [号]2 [頁]781 -786 （2024年） [査読] 有
[DOI] [3]. Robot-assisted radical nephroureterectomy for upper urinary tract tumor: initial experience with the use of novel surgical robot system, hinotori.
Translational cancer research [巻]12 [号]12 [頁]3522 -3529 （2023年） [査読] 有
[DOI] [4]. Robot-assisted radical nephrectomy using novel surgical robot platform, hinotori: Report of initial series of 13 cases.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]12 [頁]1175 -1179 （2023年） [査読] 有
[DOI] [5]. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Urologic oncology [巻]41 [号]11 [頁]458.e9 -458.e19 （2023年） [査読] 有
[DOI] [6]. Perioperative outcomes of robot-assisted partial nephrectomy using hinotori versus da Vinci surgical robot system: a propensity score-matched analysis.
Journal of robotic surgery [巻]17 [号]5 [頁]2435 -2440 （2023年） [査読] 有
[DOI] [7]. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]9 [頁]772 -777 （2023年） [査読] 有
[DOI] [8]. Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model.
Scientific reports [巻]13 [号]1 [頁]11361 （2023年） [査読] 有
[DOI] [9]. Robot-assisted adrenalectomy using a hinotori surgical robot system: Report of first series of six cases.
Asian journal of endoscopic surgery [巻]16 [号]3 [頁]489 -495 （2023年） [査読] 有
[DOI] [10]. Initial Experience of Robot-Assisted Partial Nephrectomy Using Hinotori Surgical Robot System: Single Institutional Prospective Assessment of Perioperative Outcomes in 30 Cases.
Journal of endourology [巻]37 [号]5 [頁]531 -534 （2023年） [査読] 有
[DOI] [11]. Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]1 [頁]57 -61 （2023年） [査読] 有
[DOI] [12]. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
International journal of urology : official journal of the Japanese Urological Association [巻]30 [号]9 [頁]730 -736 （2022年） [査読] 有
[DOI] [13]. ロボット支援下前立腺全摘除術(RARP)施行前後における勃起機能がQOLに与える影響について
日本性機能学会雑誌 (一社)日本性機能学会 [巻]37 [号]3 [頁]187 -188 （2022年） [査読] 無
[14]. Effects of Changes in Erectile Function After Holmium Laser Enucleation of the Prostate on Postoperative Outcomes in Patients With Benign Prostatic Hyperplasia.
In vivo (Athens, Greece) [巻]36 [号]6 [頁]2960 -2964 （2022年） [査読] 有
[DOI] [15]. Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.
Targeted oncology [巻]17 [号]5 [頁]583 -589 （2022年） [査読] 有
[DOI] [機関リポジトリ][16]. Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy.
International journal of urology : official journal of the Japanese Urological Association [巻]29 [号]9 [頁]956 -961 （2022年） [査読] 有
[DOI] [17]. Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer.
Japanese journal of clinical oncology [巻]52 [号]8 [頁]944 -949 （2022年） [査読] 有
[DOI] [18]. Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer.
Japanese journal of clinical oncology [巻]52 [号]8 [頁]944 -949 （2022年） [査読] 有
[DOI] [19]. Impact of Bladder Neck Angle Measured by Postoperative Magnetic Resonance Imaging on Midterm Recovery of Urinary Continence in Prostate Cancer Patients Undergoing Robot-Assisted Radical Prostatectomy.
Journal of endourology [巻]35 [号]11 [頁]1610 -1615 （2021年）
[DOI] [20]. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Japanese journal of clinical oncology [巻]51 [号]5 [頁]810 -818 （2021年）
[DOI] [21]. Pembrolizumab Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer.
In vivo (Athens, Greece) [巻]35 [号]3 [頁]1889 -1894 （2021年）
[DOI] [22]. Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.
Cancer diagnosis & prognosis [巻]1 [号]3 [頁]201 -205 （2021年）
[DOI] [23]. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Urologic oncology [巻]39 [号]1 [頁]78.e1 -78.e8 （2021年）
[DOI] [24]. Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: A single institution retrospective study.
Molecular and clinical oncology [巻]13 [号]3 [頁]16 （2020年）
[DOI] [25]. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Cancer science [巻]111 [号]7 [頁]2460 -2471 （2020年）
[DOI] [26]. Second transurethral resection for high-risk non-muscle invasive bladder cancer patients: a propensity score matched analysis.
Japanese journal of clinical oncology [巻]50 [号]6 [頁]718 -721 （2020年）
[DOI] [27]. Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Molecular and clinical oncology [巻]12 [号]5 [頁]495 -500 （2020年）
[DOI] [28]. Predictive factors for persistence of preoperative overactive bladder symptoms after transvaginal mesh surgery in women with pelvic organ prolapse.
Lower urinary tract symptoms [巻]12 [号]2 [頁]167 -172 （2020年）
[DOI] [29]. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Anticancer research [巻]40 [号]2 [頁]1101 -1106 （2020年）
[DOI] [30]. Improved perioperative outcomes by early unclamping prior to renorrhaphy compared with conventional clamping during robot-assisted partial nephrectomy: a propensity score matching analysis.
Journal of robotic surgery [巻]14 [号]1 [頁]47 -53 （2020年）
[DOI] [31]. Enhanced Sensitivity to NVP-BEZ235 by Inhibition of p62/SQSTM1 in Human Bladder Cancer KoTCC-1 Cells Both and .
In vivo (Athens, Greece) [巻]34 [号]3 [頁]1001 -1008 （2020年）
[DOI] [32]. ニボルマブにて急性拒絶反応を認めた転移性腎癌を有する腎移植患者の1例
腎癌研究会会報 (一社)腎癌研究会 [号]50 [頁]26 -26 （2020年） [査読] 無
[33]. Initial learning curve for robot-assisted partial nephrectomy performed by a single experienced robotic surgeon.
Asian journal of endoscopic surgery [巻]13 [号]1 [頁]59 -64 （2020年）
[DOI] [34]. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy.
Urologic oncology [巻]38 [号]1 [頁]6.e9 -6.e16 （2020年）
[DOI] [35]. Significant impact of three-dimensional volumetry of perinephric fat on the console time during robot-assisted partial nephrectomy.
BMC urology [巻]19 [号]1 [頁]132 （2019年）
[DOI] [36]. Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study.
International neurourology journal [巻]23 [号]4 [頁]327 -333 （2019年）
[DOI] [37]. Development of a Complete En-Bloc Technique with Direct Bladder Neck Incision: A Newly Modified Approach for Holmium Laser Enucleation of the Prostate.
Journal of endourology [巻]33 [号]10 [頁]835 -840 （2019年）
[DOI] [38]. Early Single-Center Experience with Robotic Partial Nephrectomy Using the da Vinci Xi: Comparative Assessment with Conventional Open Partial Nephrectomy.
Current urology [巻]13 [号]1 [頁]13 -18 （2019年）
[DOI] [39]. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.
International journal of clinical oncology [巻]24 [号]7 [頁]842 -847 （2019年）
[DOI] [40]. Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia.
Lower urinary tract symptoms [巻]11 [号]2 [頁]O141 -O146 （2019年）
[DOI] [41]. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Anticancer research [巻]39 [号]3 [頁]1391 -1396 （2019年）
[DOI] [42]. Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry.
Oncotarget [巻]10 [号]18 [頁]1688 -1703 （2019年）
[DOI] [43]. Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
Anticancer research [巻]39 [号]2 [頁]1067 -1072 （2019年）
[DOI] [44]. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma.
Medical oncology (Northwood, London, England) [巻]35 [号]10 [頁]133 （2018年）
[DOI] [45]. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
Anticancer research [巻]38 [号]7 [頁]4179 -4185 （2018年）
[DOI] [46]. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Anticancer research [巻]38 [号]6 [頁]3593 -3599 （2018年）
[DOI] [47]. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
International journal of clinical oncology [巻]23 [号]3 [頁]553 -558 （2018年）
[DOI] [48]. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
International journal of clinical oncology [巻]23 [号]3 [頁]576 -583 （2018年）
[DOI] [49]. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Clinical genitourinary cancer [巻]16 [号]3 [頁]219 -225 （2018年）
[DOI] [50]. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Medical oncology (Northwood, London, England) [巻]34 [号]12 [頁]200 （2017年）
[DOI] [51]. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Medical oncology (Northwood, London, England) [巻]34 [号]8 [頁]141 （2017年）
[DOI] [52]. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Clinical genitourinary cancer [巻]15 [号]4 [頁]e591 -e597 （2017年）
[DOI] [53]. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Urologic oncology [巻]35 [号]6 [頁]432 -437 （2017年）
[DOI] [54]. Comparison of Tyrosine Kinase Inhibitor Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma.
Anticancer research [巻]37 [号]3 [頁]1523 -1528 （2017年）
[DOI] [55]. [AN ISOLATED INTERNAL ARTERY ANEURYSM WITH COMPLETE THROMBOTIC OCCLUSION FOR WHICH PREOPERATIVE DIAGNOSIS WAS DIFFICULT: A CASE REPORT].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology [巻]106 [号]1 [頁]49 -52 （2015年）
[DOI] [56]. [Long-term survival of metastatic clear cell adenocarcinoma of the female urethra by multidisciplinary treatment: a case report].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology [巻]104 [号]3 [頁]549 -53 （2013年）
[DOI] [57]. [Bilateral adrenal hemorrhage due to adrenal metastasis of lung cancer].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology [巻]104 [号]1 [頁]17 -21 （2013年）
[DOI]